Signature probiotic and pharmacological attributes of lactic acid bacteria isolated from human breast milk

Javed, Ghulam Ayesha; Arshad, Najma; Munir, Aneela; Khan, Shafaat Yar; Rasheed, Sana; Hussain, Iqra

doi:10.1016/j.idairyj.2021.105297

Cited by 13 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The fresh cultures were centrifuged at 12,000 g for 15 min to remove the cells, the supernatant was collected and used for estimation of antagonistic activity against Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 8739, Pseudomonas aeruginosa ATCC 27853 and Clostridium perfringens ATCC 13124 using well diffusion assay (Javed et al, 2022).…”

Section: Methodsmentioning

confidence: 99%

Levilactobacillus brevis from carnivores can ameliorate hypercholesterolemia: In vitro and in vivo mechanistic evidence

Munir

Javed

et al. 2022

Journal of Applied Microbiology

Self Cite

View full text Add to dashboard Cite

Aims:The aim was to explore the probiotic and hypocholesterolaemic potential of two Levilactobacillus brevis strains of carnivore origin along with selected underlying mechanisms. Methods and Results: Levilactobacillus brevis MT950194 and L. brevis MW365351 were analysed in vitro for oro-gastro-intestinal stress tolerance, cholesterol reduction, cholesterol adsorption (through scanning electron microscopy) and bile salt hydrolase (BSH) activity. Strains could survive (>80%) in oro-gastro-intestinal conditions and reduce high amount of cholesterol (35% and 54%) from media containing bile salts (0.3%) as compared with Lactobacillus acidophilus ATCC 4356 and presented the least pathogenicity towards mammalian cells. Exopolysaccharide production, cell surface cholesterol adherence and BSH activity were witnessed as possible cholesterol-lowering mechanisms. In in vivo experiment, the treatments of hypercholesterolaemic rats with L. brevis MT950194, L. brevis MW365351 and their mixture led to significant (p < 0.05) reduction in serum and hepatic cholesterol, low-density lipids, cholesterol ratio, liver steatosis and size of adipocytes. It further ameliorated diet-induced changes in hepatic enzymes. Conclusions: Levilactobacillus brevis MT950194 and L. brevis MW365351 from carnivores have probiotic pharmacological potential and can reduce serum cholesterol through surface adherence and BSH production. Significance and Impact of the Study: These strains may be utilized in treating hypercholesterolaemia and production of low-fat functional foods.

show abstract

Section: Methodsmentioning

confidence: 99%

Levilactobacillus brevis from carnivores can ameliorate hypercholesterolemia: In vitro and in vivo mechanistic evidence

Munir

Javed

et al. 2022

Journal of Applied Microbiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Adherence property to hydrocarbons also indicates ability of strains to attach with intestinal cells. Hydrophobicity > 40 % is considered as selection criteria for probiotics ( Rajoka et al, 2017 , Javed et al, 2022 ). All the selected isolates presented > 50 % hydrophobicity, while highest hydrophobicity (72 %) was recorded for L. brevis MZ384011.…”

Section: Discussionmentioning

confidence: 99%

Lead biosorption efficiency of Levilactobacillus brevis MZ384011 and Levilactobacillus brevis MW362779: A response surface based approach

Mushtaq

Arshad

Hameed

et al. 2023

Saudi Journal of Biological Sciences

View full text Add to dashboard Cite

“…Furthermore, DNase activity was not observed in any of the LAB strains isolated from breast milk [159]. In most of the studies investigating the DNase activity of LAB, it was concluded that these acidophilic bacteria do not show DNase activity and are safe in this regard [155][156][157][158][159].…”

Section: Dnase Activitymentioning

confidence: 98%

The Impacts of Acidophilic Lactic Acid Bacteria on Food and Human Health: A Review of the Current Knowledge

Icer,

Özbay,

Ağagündüz

et al. 2023

Foods

View full text Add to dashboard Cite

The need to improve the safety/quality of food and the health of the hosts has resulted in increasing worldwide interest in acidophilic lactic acid bacteria (LAB) for the food, livestock as well as health industries. In addition to the use of acidophilic LAB with probiotic potential for food fermentation and preservation, their application in the natural disposal of acidic wastes polluting the environment is also being investigated. Considering this new benefit that has been assigned to probiotic microorganisms in recent years, the acceleration in efforts to identify new, efficient, promising probiotic acidophilic LAB is not surprising. One of these effots is to determine both the beneficial and harmful compounds synthesized by acidophilic LAB. Moreover, microorganisms are of concern due to their possible hemolytic, DNase, gelatinase and mucinolytic activities, and the presence of virulence/antibiotic genes. Hence, it is argued that acidophilic LAB should be evaluated for these parameters before their use in the health/food/livestock industry. However, this issue has not yet been fully discussed in the literature. Thus, this review pays attention to the less-known aspects of acidophilic LAB and the compounds they release, clarifying critical unanswered questions, and discussing their health benefits and safety.

show abstract

Signature probiotic and pharmacological attributes of lactic acid bacteria isolated from human breast milk

Cited by 13 publications

References 34 publications

Levilactobacillus brevis from carnivores can ameliorate hypercholesterolemia: In vitro and in vivo mechanistic evidence

Levilactobacillus brevis from carnivores can ameliorate hypercholesterolemia: In vitro and in vivo mechanistic evidence

Lead biosorption efficiency of Levilactobacillus brevis MZ384011 and Levilactobacillus brevis MW362779: A response surface based approach

The Impacts of Acidophilic Lactic Acid Bacteria on Food and Human Health: A Review of the Current Knowledge

Contact Info

Product

Resources

About